ftInvstr

HESTERBIO · Healthcare ₹2391.0 +9.5% Mkt Cap ₹2059 Cr overvalued

HESTERBIO

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹2391.0

+9.5% today · 30d -3.2%

as of 2026-09-04

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for HESTERBIO. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-06-30

REVENUE

₹77 Cr

-8.16% YoY

NET PROFIT

₹97 Cr

+459.27% YoY

OPM

30.96%

+1.88pp YoY

EPS

₹113.71

PE 14.88

Intrinsic value · DCF ₹811.26 · Margin of safety -66.1% (overvalued) · FCF yield 2.25%

◇ Sector Position

PEERPEROCE %

HESTERBIO14.8815.0

SUNPHARMA37.5721.44

DIVISLAB89.1821.56

ZYDUSLIFE24.6424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance STRONG 75

Valuation CHEAP 75

Growth STEADY 68

Profitability HIGH 85

Technicals NEUTRAL 57

Risk MODERATE 50

Key Stats

TTM PE

14.88

P/B

5.58

52W HIGH

₹2683.6

OFF HIGH

-10.9%

DIV YIELD

0.46%

MKT CAP

₹2059 Cr

◉ Active Signals

MACDBearish-15.5924

RSI(14)Neutral54.2

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold HESTERBIO and at what entry.